美国国立卫生研究院卒中量表作为卒中研究结局:协方差分析优于分析基线变化值
本文讨论卒中研究中以美国国立卫生研究院卒中量表(NIHSS)为结局时,分析随访NIHSS较基线变化值(ΔNIHSS)存在重要局限,而采用协方差分析(ANCOVA)以随访NIHSS为因变量并调整基线NIHSS可减少结局变异性、提高检验效能,作者通过临床试验模拟展示该优势并反对简单双变量比较绝对变化值。
要点
- 分析ΔNIHSS隐含基线NIHSS与随访NIHSS关系的强假设,该假设难以满足,可能影响统计效度。
- ANCOVA以随访NIHSS为因变量、基线NIHSS为协变量,可减少结局变异性并提高检验效能。
- 作者通过临床试验模拟展示ANCOVA优于简单双变量比较绝对NIHSS变化值,并警示不要使用后者。
核心结论
- 使用ANCOVA分析随访NIHSS并调整基线NIHSS优于简单双变量比较绝对NIHSS变化值,作者警示不要使用后者。
研究设计与样本
- 本文使用临床试验模拟来阐述方法学问题。
主要发现
- 临床试验模拟显示,随访NIHSS调整基线后结局变异性小于ΔNIHSS,且变异性降低提高检验效能。
- 分析ΔNIHSS隐含基线NIHSS与随访NIHSS关系的强假设,该假设不太可能满足,使统计分析效度存疑。
- 简单双变量比较(如t检验、Wilcoxon秩和检验、未调整基线的线性回归)分析ΔNIHSS存在局限性,降低治疗效应估计精度和临床试验效能。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
National Institutes of Health Stroke Scale (NIHSS), measured a few hours to days after stroke onset, is an attractive outcome measure for stroke research. NIHSS at the time of presentation (baseline NIHSS) strongly predicts the follow-up NIHSS. Because of the need to account for the baseline NIHSS in the analysis of follow-up NIHSS as an outcome measure, a common and intuitive approach is to define study outcome as the change in NIHSS from baseline to follow-up (ΔNIHSS). However, this approach has important limitations. Analyzing ΔNIHSS implies a very strong assumption about the relationship between baseline and follow-up NIHSS that is unlikely to be satisfied, drawing into question the validity of the resulting statistical analysis. This reduces the precision of the estimates of treatment effects and the power of clinical trials that use this approach to analysis. ANCOVA allows for the analysis of follow-up NIHSS as the dependent variable while adjusting for baseline NIHSS as a covariate in the model and addresses several challenges of using ΔNIHSS outcome using simple bivariate comparisons (eg, a t test, Wilcoxon rank-sum, linear regression without adjustment for baseline) for stroke research. In this article, we use clinical trial simulations to illustrate that variability in NIHSS outcome is less when follow-up NIHSS is adjusted for baseline compared to ΔNIHSS and how a reduction in this variability improves the power. We outline additional, important clinical and statistical arguments to support the superiority of ANCOVA using the final measurement of the NIHSS adjusted for baseline over, and caution against using, the simple bivariate comparison of absolute NIHSS change (ie, delta).
引用
- Mistry EA, Yeatts SD, Khatri P, et al. National Institutes of Health Stroke Scale as an Outcome in Stroke Research: Value of ANCOVA Over Analyzing Change From Baseline. Stroke. 2022. PMID: 35012328. doi:10.1161/STROKEAHA.121.034859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。